<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82752">
  <stage>Registered</stage>
  <submitdate>11/04/2008</submitdate>
  <approvaldate>15/04/2008</approvaldate>
  <actrnumber>ACTRN12608000201370</actrnumber>
  <trial_identification>
    <studytitle>A randomized double-blind placebo-controlled trial to assess the effects of 17 beta-oestradiol 1mg + drospirenone 2mg administration on cognitive function in early postmenopausal women.</studytitle>
    <scientifictitle>A randomized double-blind placebo-controlled trial to assess the effects of 17 beta-oestradiol 1mg + drospirenone 2mg administration on cognitive function in early postmenopausal women.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>cognition</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>administration of 17 beta-oestradiol 1mg and drospirenone 2mg orally once per day  for 26 weeks</interventions>
    <comparator>placebo - sugar pill. Orally once per day for 26 weeks</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>effects on cognition as measured by functional Magnetic Resonance Imaging (fMRI)</outcome>
      <timepoint>26 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>effects on cognition as measured by Cogstate</outcome>
      <timepoint>26 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>healthy postmenopausal women on no hormonal replacement therapy for the previous 12 months, who have had at least 12 months of amenorrhea but no more than 5 years of amenorrhea or who have become surgically menopausal by bilateral oophorectomy at least 4 weeks previously.</inclusivecriteria>
    <inclusiveminage>45</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>history of cancer in past 5 years excluding non-melanotic skin cancer; deep venous thrombosis; pulmonary embolism, retinal vein thrombosis;significant heart, liver, kidney endocrine or neurological disease; significant head injury, epilepsy, cerebral tumour, stroke, previous intracranial surgery, Parkinson's disease, multiple sclerosis, intellectual disability; uncontrolled hypertension; undiagnosed genital bleeding; severe depression, severe psychiatric illness, current use of antidepressant medication; current smoking history, alcohol consumption greater than 3 standard drinks per day; no mammogram or Pap Smear in past 2 years or Body Mass Index &lt;18 or &gt;40kg/m^2</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>allocation involved contacting the holder of the allocation schedule who was at central administration</concealment>
    <sequence>Simple randomisation by using a randomization table created by a computer software (i.e., computerised sequence generation)</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/06/2008</anticipatedstartdate>
    <actualstartdate>11/11/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate>22/09/2010</actualenddate>
    <samplesize>40</samplesize>
    <actualsamplesize>23</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Women's Health Program, Monash University</primarysponsorname>
    <primarysponsoraddress>Monash Medical School
Alfred Hospital
Commercial Rd
Prahran 3181</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Bayer Schering Pharma</fundingname>
      <fundingaddress>875 Pacific Highway 
Pymble NSW 2073</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A 26 week study to assess the efficacy of 17 beta-oestradiol and drosperinone on cognitive function in healthy postmenopausal women aged 45-55 years.</summary>
    <trialwebsite>http:womenshealth.med.monash.edu.au</trialwebsite>
    <publication>Davison SL, Bell RJ, Robinson PJ, Jane F, Leech J, Maruff P, Egan GF, Davis SR. Continuous-combined oral estradiol/drospirenone has no detrimental effect on cognitive performance and improves estrogen deficiency symptoms in early postmenopausal women: a randomized placebo-controlled trial. Menopause. 2013 Oct;20(10): 1020-1026</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Monash University Human Research Ethics Committee (MUHREC)</ethicname>
      <ethicaddress>Human Ethics Office First Floor,
Building 3E, Room 111
Monash University Clayton Campus,
Wellington Rd, Clayton,
VIC 3800</ethicaddress>
      <ethicapprovaldate>4/09/2008</ethicapprovaldate>
      <hrec>CF08/1572 - 2008000801</hrec>
      <ethicsubmitdate>30/05/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Susan Davis</name>
      <address>Women's Health Research Program
Monash University
Level 6,  The Alfred Centre
99 Commercial Rd
Melbourne Victoria 3004</address>
      <phone>+61 3 9903 0827</phone>
      <fax>+61 3 9903 0828</fax>
      <email>susan.davis@monash.edu</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Susan Davis</name>
      <address>Women's Health Research Program
Monash University
Level 6,  The Alfred Centre
99 Commercial Rd
Melbourne Victoria 3004</address>
      <phone>+61 3 9903 0837</phone>
      <fax>+61 3 9903 0828</fax>
      <email>susan.davis@monash.edu </email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>susan davis</name>
      <address>Women's Health Research Program
Monash University
Level 6,  The Alfred Centre
99 Commercial Rd
Melbourne Victoria 3004</address>
      <phone>+61 3 9903 0827</phone>
      <fax>+61 3 9903 0828</fax>
      <email>susan.davis@monash.edu</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Susan Davis</name>
      <address>Women's Health Research Program
Monash University
Level 6,  The Alfred Centre
99 Commercial Rd
Melbourne Victoria 3004</address>
      <phone>+61 3 99030827</phone>
      <fax>+613 99030828</fax>
      <email>susan.davis@monash.edu</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>